<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000909.v1.p1" parentStudy="phs000909.v1.p1" createDate="2015-05-01" modDate="2015-06-18">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Himisha Beltran</td><td>Weill Cornell Medical College, New York, NY, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Levi A. Garraway</td><td>Dana-Farber Cancer Institute, Broad Institute, Cambridge, MA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Mark Rubin</td><td>Weill Cornell Medical College, New York, NY, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Francesca Demichelis</td><td>University of Trento, Italy</td></tr>
		<tr><td>Funding Source</td><td>U54 HG003067</td><td>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Neuroendocrine Prostate Cancer (Trento/Cornell/Broad 2015)</StudyNameEntrez>
	<StudyNameReportPage>Molecular Basis of Neuroendocrine Prostate Cancer (Trento/Cornell/Broad 2015)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>A subset of advanced prostate cancers can progress from an androgen receptor (AR)-driven state to AR independence, often associated with low or absent AR expression and extensive neuroendocrine differentiation. Once neuroendocrine prostate cancer (NEPC) develops, patients typically demonstrate an aggressive clinical course and poor overall survival. Early diagnosis is important but remains challenging as the clinical and pathologic features associate with AR independence and NEPC are poorly defined. We performed whole exome sequencing of 114 metastatic tumors from 81 patients (35 with morphologic features of NEPC). Serial or synchronous samples were included to characterize heterogeneity and the transition from adenocarcinoma to NEPC. Computational analysis of clonality and allele specific quantification were performed using CLONET. Quantitative mRNA assessment including AR signaling genes and DNA methylation were evaluated in the context of genomic changes.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Patients with prostate cancer were eligible for inclusion in this study. Cases included tumor tissue, and controls were patient matched blood or benign tissue.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="22389870"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25160065"/>
		</Publication>
		<Publication>
			<Pubmed pmid="24705311"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Adenocarcinoma"/>
		<Disease vocab_source="MESH" vocab_term="Prostatic Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Neuroendocrine tumors"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Himisha Beltran</AttName>
			<Institution>Weill Cornell Medical College, New York, NY, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Levi A. Garraway</AttName>
			<Institution>Dana-Farber Cancer Institute, Broad Institute, Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Mark Rubin</AttName>
			<Institution>Weill Cornell Medical College, New York, NY, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Francesca Demichelis</AttName>
			<Institution>University of Trento, Italy</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U54 HG003067</AttName>
			<Institution>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01CA116337</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000909.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000909.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000909.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
